News

NeedleSmart PRO Receives FDA Approval

Published on: 12/04/2021

NeedleSmart PRO Receives FDA Approval
Covid-19
Member News

The award-winning NeedleSmart PRO needle destruction device has achieved FDA approval as a Class II medical device.

Merseyside Based NeedleSmart Ltd is the FIRST UK company to achieve FDA 510(k) approval (Class II for Sharps Needle Destruction Device (NDD).

The innovative NeedleSmart PRO device heats a sharp, contaminated hypodermic needle to 1,300, then compresses the molten metal into a smooth ball at the end of the syringe, removing the danger of needlestick injury and infection in just 6 seconds.

NeedleSmart’s patented technology is engineered in the UK, with offices in Knowsley, Merseyside (UK), and recently opened Pittsburgh, Pennsylvania (USA).

The NeedleSmart PRO will be used in clinical environments including hospitals and GP surgeries, and will be used in digital vaccination programmes and immunisations based in the North West.

The device offers many benefits

  • Reduction of needlestick injuries (NSI) and associated costs both emotional and financial.
  • Sustainability approx. 25% reduction in sharps bin requirement, leading to less waste, and contributing to the overall carbon footprint in the medical sector.
  • Potential introduction of clinisafe bag/box as no longer a sharp.
  • Along with associated software, the device will be used to digitalise vaccination data seamlessly, securely and safely.

Merseyside based NeedleSmart CEO Cliff Kirby added: “I am absolutely thrilled that the NeedleSmart PRO has received FDA approval. Knowing we are the first UK Company to achieve this is a fantastic achievement and pays testament to the product and expertise of our team, and we are looking forward new distribution partnerships in the USA.”

NeedleSmart is a smart med-tech business focused on better health results including safety, clinical process efficiency, cost management, and digitisation of clinical events, whilst improving sustainability. FDA approval marks a milestone in NeedleSmart’s geographic expansion to serve the North American market.

For more information & images please contact:

julie@needlesmart.com

+44 (0)7850630004

T: +44 (0)151 315 0500 (UK)

T: +1 (717) 8561296 (USA)

needlesmart.com

digitalvaccination.com

NEWS​

Related News

New Round Tables announced to drive progress on EHDS and health AI

3 Jul 2025

The European Accessibility Act Is Here. Are You Ready?

2 Jul 2025
Why inclusive design is no longer optional – and how Big Motive can help you lead the way.

DTH-Lab Director: The G7 must act now to address the digital health transformation

2 Jul 2025
As digital platforms increasingly shape health systems and information flows, the G7 must lead in setting global standards to ensure safety, equity an...

InnoHSupport Open Calls

1 Jul 2025
Welcome to the InnoHSupport Open Calls!

Transformative Health Instrument Call 2025

1 Jul 2025
Apply to the Transformative Health Instrument (THI) Call 2025 if you are a growing and innovative healthcare start-up working on solutions that have s...

Longitude Prize on ALS

1 Jul 2025
The £7.5 million (~$10 million) Longitude Prize on ALS incentivises the use of AI-based approaches to transform drug discovery for amyotrophic lateral...

Become a member

Join ECHAlliance to amplify your organisation’s message, grow your networks, connect with innovators and collaborate globally.
 
First name *
Last Name *
Email Address *
Country *
Position *
First name *
Last Name *
Email Address *
Country *
Position *